Navigation Links
Transgenomic, Inc. Reports Second Quarter 2009 Results
Date:8/12/2009

===== === ======= === BASIC AND DILUTED INCOME (LOSS) PER SHARE: $(0.01) $0.00 $(0.03) $0.00 ====== ===== ====== ===== BASIC WEIGHTED AVERAGE SHARES OUTSTANDING 49,189,672 49,189,672 49,189,672 49,189,672 DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING 49,189,672 49,301,010 49,189,672 49,301,010

                              Transgenomic, Inc.
                          Summary Financial Results
          Unaudited Condensed Consolidated Statements of Cash Flows
                            (Dollars in thousands)


                                                         Six Months Ended
                                                             June 30,
                                                             --------
                                                         2009        2008
                                                         ----        ----
    NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES       193         193

    NET CASH FLOWS USED IN INVESTING ACTIVITIES          (232)       (131)

    EFFECT OF FOREIGN CURRENCY EXCHANGE RATE
     CHANGES ON CASH                                       44         (93)
                                                          ---        ----

    NET CHANGE IN CASH AND CASH EQUIVALENTS                 5         (31)

    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD    4,771       5,723
                                                        -----       -----

    CASH AND CASH EQUIVALENTS AT END OF PERIOD         $4,776      $5,692
                                                       ======      ======




                                  Transgenomic, Inc.
                              Summary Financial Results
                        Condensed Con
'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Announces Appointment of New Board Members
2. Transgenomic, Inc. Reports First Quarter 2009 Results
3. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
4. Transgenomic, Inc. Reports Third Quarter 2008 Results
5. Transgenomic, Inc. Forms Scientific Advisory Board
6. Transgenomic, Inc. Reports Second Quarter 2007 Results
7. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
8. Oncothyreon reports second quarter 2009 financial results
9. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
10. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... and TORONTO , June 2, ... TSX: APS), a clinical-stage company developing new therapeutics that ... the U.S. Food and Drug Administration (FDA) has granted ... treatment of acute myeloid leukemia (AML). APTO-253, a first-in-class ... product candidate in a Phase Ib clinical trial in ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ... Diagnostics - Global Market Size, Strategy and Forecasts - ... "Molecular Diagnostics - Global Market Size, Strategy and ... and planners can use. Hundreds of pages of information ... Medicare Fee Payment Schedules to help understand test pricing ...
(Date:6/2/2015)... June 02, 2015 Cirrascale ... blade-based and rackmount computing and storage infrastructure for ... launch of its high density scale-out, two-in-one video ... Slipstream™ RM1622D . The high density, two-in-one system ... product family with Intel® Iris™ Pro graphics P6300 ...
(Date:6/2/2015)... , June 2, 2015   BioClinica ® ... technology provider, today announced that David Peters , ... named Executive Vice President and Chief Financial Officer (CFO) ... Peters brings more than 25 years of ... services. "David has extensive and deep knowledge in all ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3BioClinica Names David Peters New Chief Financial Officer 2
... demand for low-cost, small-size, high-speed, highly functional and ... 60 GHz radio chipsets in semiconductor technology have ... circuit board solutions are not able to meet ... 64 GHz frequency band, while the conventional antenna ...
... BSX ) today announced financial results for the third,quarter ... sales and,earnings per share (EPS) for the fourth quarter of ... sales of $1.978 billion and adjusted EPS of $0.16 ... Achieved worldwide cardiac rhythm management (CRM) sales growth of 11 ...
... percentage comparisons are to comparable periods in,2007):, -- Q3 2008 ... increased 7.4% to $540.6 million. Currency added 3.1% to organic ... 7.0% for the Company,s Research-based sales units was ... six months of 2008. Q3 2008 currency adjusted sales for SAFC ...
Cached Biology Technology:NTU and SIMTech announce the first antenna-in-package solution for single-chip 60 GHz radio 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... Sequencing Center at Washington University School of Medicine increased ... additional Genome Sequencer FLX Systems from Roche Diagnostics. ... the Genome Sequencing Center will be able to support ... technology, ranging from the sequencing of new complex genomes ...
... of new genome sequencing technology has prompted a ... hypothesis about how agricultures early beginnings may have ... Vinatzer, assistant professor of plant pathology, physiology, and ... Life Sciences, has received a $1 million, five-year ...
... the New York-based Doris Duke Charitable Foundation (DDCF), Carnegie ... of investigators from Carnegie Mellon, the University of Minnesota, ... law firm Van Ness Feldman to develop and promote ... transport and deep geological sequestration of carbon dioxide (CO ...
Cached Biology News:Washington University increases fleet of Roche Genome Sequencer FLX Systems 2Washington University increases fleet of Roche Genome Sequencer FLX Systems 3Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Carnegie Mellon receives $1.85 million 2
... 50mM Tris-HCl, pH 7.5, 0.1mM ... 1mM benzamidine, 0.1% 2-mercaptoethanol and ... Phosphatase 2A1) partially purified enzyme ... QSepharose,amino-hexyl agarose, Superdex 200, and ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
... : Recombinant human HMGN2/HMG-17 Formulation: ... 0.15M NaCl, 0.05% sodium azide ... to 30% Quality Assurance: routinely ... extracts of murine 10T 1/2 ...
Biology Products: